Omega-3 fatty acids ( DrugBank: Omega-3 fatty acids, Omega-3 )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2
79	Homozygous familial hypercholesterolemia	1

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02133664 (ClinicalTrials.gov)	June 2014	6/5/2014	Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis	Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis	Multiple Sclerosis;Cognition	Drug: lipoic acid and omega-3 fatty acids;Drug: Placebo	Oregon Health and Science University	National Multiple Sclerosis Society	Completed	18 Years	65 Years	All	54	Phase 1/Phase 2	United States
2	NCT00360906 (ClinicalTrials.gov)	December 2004	4/8/2006	Omega-3 Fatty Acid Treatment in Multiple Sclerosis	Omega-3 Fatty Acid Treatment in Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Drug: Triomar™ (omega-3 fatty acids)	Haukeland University Hospital	The Multiple Sclerosis National Competence Centre;The Norwegian Multiple sclerosis Society;Pronova BioPharma;Serono Nordic;Amersham Health	Completed	18 Years	55 Years	Both	100	Phase 2/Phase 3	Norway

79. Homozygous familial hypercholesterolemia

---

Clinical trials : 142 /  Drugs : 114 - (DrugBank : 29) / Drug target genes : 9 - Drug target pathways : 18

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03510715 (ClinicalTrials.gov)	August 31, 2018	18/4/2018	An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia	An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia	Hypercholesterolemia	Drug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Nicotinic acid;Drug: Fenofibrate;Drug: Omega-3 fatty acids;Drug: Atorvastatin;Drug: Simvastatin;Drug: Fluvastatin;Drug: Pravastatin;Drug: Lovastatin	Sanofi	Regeneron Pharmaceuticals	Completed	8 Years	17 Years	All	18	Phase 3	Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;France;Italy;Norway;United States